Galderma Laboratories has received FDA approval for Vectical ointment (calcitriol 3mcg/g), a vitamin D3 product, for the treatment of mild-to-moderate plaque psoriasis in adults. This approval was based on two 8-week studies that compared Vectical ointment versus a vehicle treatment. In the first study, improvements in mild-to-moderate plaque psoriasis severity began at week 2 and were sustained over the 8-week treatment period. By the end of the study, 34% of Vectical treated patients achieved treatment success versus 22% of those treated with vehicle. Vectical8482; Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in patients 18 years and older. The most frequent adverse events reported in clinical trials (>3%) were lab test abnormality, urine abnormality, psoriasis, hypercalciuria, pruritus and skin discomfort. Vectical8482; should be used with caution in patients with 法国高德美(Galderma)制药公司宣布,该公司的3 μg/g Vectical(骨化三醇)软膏获美国FDA批准,该产品是美国唯一经批准用于治疗成人轻度和中度斑块状银屑病的维生素D3产品。 【Vectical如何作用?】 VECTICAL OINTMENT
Calcitriol 3mcg/g; oint. Rx Vitamin D3 derivative. Galderma Laboratories, Inc. Indications for VECTICAL OINTMENTTopical treatment of mild to moderate plaque psoriasis. Adult dose for VECTICAL OINTMENT≥18 years: Apply to affected areas of the body twice daily (AM & PM). The maximum weekly dose should not exceed 200g. Children's dosing for VECTICAL OINTMENT<18 years: not recommended. Warnings/Precautions for VECTICAL OINTMENTDiscontinue if hypercalcemia occurs (until normocalcemia returns). Avoid applying to eyes, lips, or facial skin. Avoid excessive exposure to natural or artificial light (tanning booths, sun lamps). Consider limiting or avoiding use of phototherapy. Pregnancy (Cat.C). Nursing mothers. Interactions for VECTICAL OINTMENTCaution with concomitant use of medications known to increase serum calcium (eg, thiazide diuretics), calcium supplements or high doses of vitamin D. Adverse Reactions for VECTICAL OINTMENTHypercalcemia, lab test and urine abnormalities, psoriasis, hypercalciuria, pruritus. How is VECTICAL OINTMENT supplied?Oint—5g, 100g 2009年2月3日,Galderma公司宣布美国FDA已批准其骨化三醇软膏剂3mcg/g(calcitriol ointment, Vectical)用于18岁及以上轻微至中度斑块型银屑病患者。 本品是美国唯一一种此类VD3软膏剂。 银屑病是一种慢性皮肤病,约有2%~3%的美国人患有银屑病。其特征为皮肤出现厚、红、鳞状斑块。 此次批准是基于2项为期8周的临床研究;研究共纳入患者800多例,对比了本品(剂量:每日2次)与赋形剂的疗效。在第一项研究中,在治疗的第二周,轻微至中度银屑病严重程度的改善开始显现,并且在8周的治疗期间,其疗效维持。至该研究结束,本品组中34%的患者达到了成功治疗(总体严重程度评分GSS清除/最小化),而赋形剂组为22%。8周治疗后23%的患者治疗成功,疾病严重程度改善了2级。第二项临床研究显示了类似的疗效结果。 在本品组与赋形剂组中,与治疗相关的不良反应相似。主要的不良反应为化验异常、尿液异常、银屑病、高钙尿症、瘙痒与皮肤不适。在为期52周的长期安全性研究中,本品的不良反应事件与以上两项研究中的相似。另外,在这些研究中,虽然有血浆含钙量一过性升高事件,但据报道连续使用52周,本品对钙平衡无显著临床效应。 目前,银屑病尚无治愈方法。其典型的局部治疗法为采用类固醇皮质激素(通常不可长期使用)或其他VD产品(对敏感皮肤褶皱具有刺激性)。本品的批准为轻微至中度斑块型银屑病患者提供了另一种局部治疗方法;对于长期治疗,本品安全、有效。 |